Prescribing Doc's Testimony Key In 2nd Philly Xarelto Trial
By Matt Fair ( April 4, 2018, 5:47 PM EDT) -- After a $28 million verdict in a bellwether Xarelto case in Philadelphia was axed over testimony that additional warnings about the drug's bleeding risks wouldn't have changed a doctor's prescribing decision, attorneys say the plaintiff in a second trial set to begin Thursday will face a challenge ensuring similar testimony doesn't derail his case....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.